BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carroll TP, O'Connor CA, Floyd O, McPartlin J, Kelleher DP, O'Brien G, Dimitrov BD, Morris VB, Taggart CC, McElvaney NG. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res 2011;12:91. [PMID: 21752289 DOI: 10.1186/1465-9921-12-91] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Belmonte I, Barrecheguren M, López-Martínez RM, Esquinas C, Rodríguez E, Miravitlles M, Rodríguez-Frías F. Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach. Int J Chron Obstruct Pulmon Dis 2016;11:2535-41. [PMID: 27877030 DOI: 10.2147/COPD.S115940] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
2 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
3 Mcelvaney NG. Diagnosing α 1 -antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev 2015;24:52-7. [DOI: 10.1183/09059180.10010814] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
4 Topic A, Stankovic M, Divac-Rankov A, Petrovic-Stanojevic N, Mitic-Milikic M, Nagorni-Obradovic L, Radojkovic D. Alpha-1-antitrypsin deficiency in Serbian adults with lung diseases. Genet Test Mol Biomarkers 2012;16:1282-6. [PMID: 22971141 DOI: 10.1089/gtmb.2012.0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
5 Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis 2017;12:561-9. [PMID: 28243076 DOI: 10.2147/COPD.S125389] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 14.8] [Reference Citation Analysis]
6 Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernández ME, Saez MS; grupo de estudio DAAT.AR. Prevalence of Alpha-1 Antitrypsin Deficiency in COPD Patients in Argentina. The DAAT.AR Study. Arch Bronconeumol (Engl Ed) 2020;56:571-7. [PMID: 31889566 DOI: 10.1016/j.arbres.2019.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
8 Greulich T, Ottaviani S, Bals R, Lepper PM, Vogelmeier C, Luisetti M, Ferrarotti I. Alpha1-antitrypsin deficiency – Diagnostic testing and disease awareness in Germany and Italy. Respiratory Medicine 2013;107:1400-8. [DOI: 10.1016/j.rmed.2013.04.023] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
9 Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol 2013;111:458-64. [PMID: 24267358 DOI: 10.1016/j.anai.2013.09.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
10 Greulich T, Averyanov A, Borsa L, Rozborilová E, Vaicius D, Major T, Chopyak V, Tudorache V, Konstantinova T, Camprubí S. European screening for alpha 1 -antitrypsin deficiency in subjects with lung disease: European screening for AAT deficiency. The Clinical Respiratory Journal 2017;11:90-7. [DOI: 10.1111/crj.12310] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
12 O’brien ME, Pennycooke K, Carroll TP, Shum J, Fee LT, O’connor C, Logan PM, Reeves EP, Mcelvaney NG. The Impact of Smoke Exposure on the Clinical Phenotype of Alpha-1 Antitrypsin Deficiency in Ireland: Exploiting a National Registry to Understand a Rare Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 2015;12:2-9. [DOI: 10.3109/15412555.2015.1021913] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
13 Franciosi AN, Carroll TP, McElvaney NG. Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians. Lancet Respir Med 2019;7:1059-67. [PMID: 31324540 DOI: 10.1016/S2213-2600(19)30141-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
14 McCarthy C, Orr C, Fee LT, Carroll TP, Dunlea DM, Hunt DJL, Dunne E, O'Connell P, McCarthy G, Kenny D, Fearon U, Veale DJ, Reeves EP, McElvaney NG. Brief Report: Genetic Variation of the α1 -Antitrypsin Gene Is Associated With Increased Autoantibody Production in Rheumatoid Arthritis. Arthritis Rheumatol 2017;69:1576-9. [PMID: 28409899 DOI: 10.1002/art.40127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 McCarthy C, Lara Gallego B, Trapnell BC, McCormack FX. Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Adv Exp Med Biol 2017;1031:419-42. [PMID: 29214586 DOI: 10.1007/978-3-319-67144-4_24] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kleinerova J, Ging P, Rutherford C, Lawrie I, Winward S, Eaton D, Redmond KC, Egan JJ. The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients. Eur Respir J 2019;53:1900055. [DOI: 10.1183/13993003.00055-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Franciosi AN, Ralph J, O'Farrell NJ, Buckley C, Gulmann C, O'Kane M, Carroll TP, McElvaney NG. Alpha-1 antitrypsin deficiency-associated panniculitis. J Am Acad Dermatol 2021:S0190-9622(21)00232-2. [PMID: 33516773 DOI: 10.1016/j.jaad.2021.01.074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Blanco I, Diego I, Bueno P, Pérez-holanda S, Casas-maldonado F, Miravitlles M. Prevalence of α 1 -antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev 2020;29:200014. [DOI: 10.1183/16000617.0014-2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Hogan G, Geoghegan P, Carroll TP, Clarke J, McElvaney OF, McElvaney OJ, McElvaney NG, Curley GF. α1-Antitrypsin: Key Player or Bystander in Acute Respiratory Distress Syndrome? Anesthesiology 2021;134:792-808. [PMID: 33721888 DOI: 10.1097/ALN.0000000000003727] [Reference Citation Analysis]
20 Annunziata A, Ferrarotti I, Coppola A, Lanza M, Imitazione P, Spinelli S, Micco PD, Fiorentino G. Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. J Clin Med 2021;10:1546. [PMID: 33916947 DOI: 10.3390/jcm10081546] [Reference Citation Analysis]
21 Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:20406223211015954. [PMID: 34408833 DOI: 10.1177/20406223211015954] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E. Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon 2012;12:e7434. [PMID: 23166537 DOI: 10.5812/hepatmon.7434] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
23 Rodriguez-frias F, Miravitlles M, Vidal R, Camos S, Jardi R. Rare alpha-1-antitrypsin variants: are they really so rare? Ther Adv Respir Dis 2012;6:79-85. [DOI: 10.1177/1753465811434320] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
24 Dunlea DM, Fee LT, McEnery T, McElvaney NG, Reeves EP. The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals. J Inflamm Res 2018;11:123-34. [PMID: 29618937 DOI: 10.2147/JIR.S156405] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
25 Hurley K, Reeves EP, Carroll TP, McElvaney NG. Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment. Expert Rev Respir Med 2016;10:207-22. [PMID: 26634397 DOI: 10.1586/17476348.2016.1127759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2020;202:73-82. [PMID: 32197047 DOI: 10.1164/rccm.202002-0262OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
27 Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, Mcelvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency. Eur Respir J 2017;50:1700610. [DOI: 10.1183/13993003.00610-2017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 91] [Article Influence: 30.8] [Reference Citation Analysis]
28 Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res 2017;18:60. [PMID: 28416015 DOI: 10.1186/s12931-017-0543-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
29 Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidiscip Respir Med 2018;13:39. [PMID: 30338069 DOI: 10.1186/s40248-018-0153-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
30 Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016;10:72-84. [PMID: 26341117 DOI: 10.1177/1753465815602162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
31 El-rayah EA, Twomey PJ, Wallace EM, Mccormick PA. Both α-1-antitrypsin Z phenotypes and low caeruloplasmin levels are over-represented in alcohol and nonalcoholic fatty liver disease cirrhotic patients undergoing liver transplant in Ireland: . European Journal of Gastroenterology & Hepatology 2018;30:364-7. [DOI: 10.1097/meg.0000000000001056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
32 de Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis 2012;6:277-95. [DOI: 10.1177/1753465812457113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 11.7] [Reference Citation Analysis]
33 Chorostowska-wynimko J. Targeted screening programmes in COPD: how to identify individuals with α 1 -antitrypsin deficiency. Eur Respir Rev 2015;24:40-5. [DOI: 10.1183/09059180.00010614] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
34 Anzueto A. Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease: A Family Perspective. COPD 2015;12:462-7. [PMID: 25474273 DOI: 10.3109/15412555.2014.974746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
35 Mccarthy C, Saldova R, Wormald MR, Rudd PM, Mcelvaney NG, Reeves EP. The Role and Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and Chronic Inflammatory Conditions. J Proteome Res 2014;13:3131-43. [DOI: 10.1021/pr500146y] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 11.4] [Reference Citation Analysis]
36 Ghosh S, Das PJ, McQueen CM, Gerber V, Swiderski CE, Lavoie JP, Chowdhary BP, Raudsepp T. Analysis of genomic copy number variation in equine recurrent airway obstruction (heaves). Anim Genet 2016;47:334-44. [PMID: 26932307 DOI: 10.1111/age.12426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 Belmonte I, Barrecheguren M, Esquinas C, Rodríguez E, Miravitlles M, Rodríguez-Frías F. Genetic diagnosis of α1-antitrypsin deficiency using DNA from buccal swab and serum samples. Clin Chem Lab Med 2017;55:1276-83. [PMID: 28107169 DOI: 10.1515/cclm-2016-0842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9-19. [PMID: 28752442 DOI: 10.1007/978-1-4939-7163-3_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
39 Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG. α1-Antitrypsin deficiency. Nat Rev Dis Primers 2016;2:16051. [PMID: 27465791 DOI: 10.1038/nrdp.2016.51] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 20.6] [Reference Citation Analysis]
40 Blanco I. A well-designed/conducted study on alpha-1 antitrypsin epidemiology not quoted. Eur Respir J 2018;51:1702662. [DOI: 10.1183/13993003.02662-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
41 Geramizadeh B, Jowkar Z, Karami L, Masoumpour M, Mehrabi S, Ghayoumi MA. Alpha-1 antitrypsin deficiency in Iranian patients with chronic obstructive pulmonary disease. Iran Red Crescent Med J 2013;15:e7508. [PMID: 24719685 DOI: 10.5812/ircmj.7508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Greulich T, Nell C, Herr C, Vogelmeier C, Kotke V, Wiedmann S, Wencker M, Bals R, Koczulla AR. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. Orphanet J Rare Dis 2016;11:75. [PMID: 27282198 DOI: 10.1186/s13023-016-0453-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
43 Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189:419-27. [PMID: 24428606 DOI: 10.1164/rccm.201311-1984OC] [Cited by in Crossref: 104] [Cited by in F6Publishing: 51] [Article Influence: 14.9] [Reference Citation Analysis]
44 Franciosi AN, Alkhunaizi MA, Woodsmith A, Aldaihani L, Alkandari H, Lee SE, Fee LT, McElvaney NG, Carroll TP. Alpha-1 Antitrypsin Deficiency and Tobacco Smoking: Exploring Risk Factors and Smoking Cessation in a Registry Population. COPD 2021;18:76-82. [PMID: 33557645 DOI: 10.1080/15412555.2020.1864725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Fitzgerald S, McElvaney NG. The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014;6:217ra1. [PMID: 24382893 DOI: 10.1126/scitranslmed.3007116] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 11.3] [Reference Citation Analysis]